D419MC00004

Research code: D419MC00004
Research name: Randomised, multicentre, open-label, comparative, global phase III research evaluating the efficacy of durvalumab and tremelimumab in combination with platinum derivative-based chemotherapy administered as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD